Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment (PICCOLETO II)
Impiego Del Pallone Medicato Per il Trattamento di Piccoli Vasi Coronarici in Confronto Con Stent Medicato - Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Age >18 years.
- Stable or unstable coronary artery disease.
- Native coronary artery lesion in vessel with diameter <2.75 mm.
- Clinical indication to percutaneous coronary intervention (PCI).
Exclusion criteria
- Enrolment in another study with any investigational drug or device.
- Acute or recent (≤48 hours) myocardial infarction.
- Creatinine clearance <50 ml/min.
- Left ventricle ejection fraction <30%.
- Any known allergy, hypersensitivity or intolerance to any drug used during or after the procedure.
- Heavily calcified and severely tortuous lesions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
OTHER: new generation DEB
drug-eluting balloon (DEB)
|
Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)
|
|
OTHER: second generation DES
standard therapy with second generation drug-eluting stent (DES)
|
Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Verify the non-inferiority of DCB
Time Frame: up to 6 months
|
the primary objective of the study is the non-inferiority of the DCB compared to DES in terms of absence of restenosis, defined as reoccurrence of stenoses of at least 50% of the lumen of the vessel at angiographic follow-up (6 months after surgery).
|
up to 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with changes of vessels lumen
Time Frame: up to 12 months
|
any differences between groups in terms of vascular changes to angiography.
|
up to 12 months
|
|
Concentration in blood chemistry
Time Frame: up to 6 months
|
changes of concentration in blood chemistry between the groups
|
up to 6 months
|
|
Number of Participants with adverse events
Time Frame: up to 12 months
|
appearance of major cardiovascular adverse events
|
up to 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PICCOLETO2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.